UNSPSC 51343001: Indinavir

This classification denotes a protease inhibitor and anti-hiv agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5W6YA9PKKH. European Medicines Agency schedules Indinavir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08174MIG. Indinavir generally arises in the molecular formula C36H47N5O4.

UNSPSC 51343001 Indinavir, a Commodity code, nominally describes a single antiretroviral pharmaceutical product, but recent state and local solicitations tagged with this code actually involve broad procurement of medical supplies, pharmaceuticals, and health-related products well beyond the specific drug. State and local governments soliciting under this code are acquiring naloxone and drug deactivation systems for community health programs, generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing, medical and first aid supplies for emergency response, and exploring direct-to-manufacturer pharmacy benefit programs. Issuing bodies include county health departments, state health and human services agencies, municipal fire departments, and multi-state cooperative purchasing alliances. The code shows fragmented activity across health departments, public safety agencies, and centralized procurement offices rather than concentration among repeat buyers.

Recent activity spans Florida, Texas, Minnesota, and Oregon. Representative opportunities include Seminole County, Florida issuing IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the City of Tampa issuing IFB 26P00145 (posted March 25, 2026, due March 13, 2026) for 169 line items of medical and first aid supplies estimated at $700,000 and sheltered exclusively for certified Small Local Business Enterprises with a 5 percent SLBE bid discount; the Minnesota Multistate Cooperative Purchasing Alliance issuing RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) to establish multi-award contracts for generic pharmaceuticals and OTC products across state and local participating facilities; and the Texas Health and Human Services Commission issuing RFI HHS0017013 (posted April 3, 2026, due April 3, 2026) to gather market intelligence on direct-to-manufacturer prescription fulfillment capabilities. The mismatch between the code's nominal scope (a single HIV/AIDS medication) and the actual procurements suggests this Commodity code is being applied inconsistently across state and local systems.